BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer

Yuhki Yokoyama, Hengrui Zhu, Jeong Heon Lee, Andrew V. Kossenkov, Sherry Y. Wu, Jayamanna M. Wickramasinghe, Xiangfan Yin, Katherine C. Palozola, Alessandro Gardini, Louise C. Showe, Kenneth S. Zaret, Qin Liu, David Speicher, Jose R. Conejo-Garcia, James E. Bradner, Zhiguo Zhang, Anil K. Sood, Tamas Ordog, Benjamin G. Bitler, Rugang Zhang

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The emergence of tumor cells with certain stem-like characteristics, such as high aldehyde dehydrogenase (ALDH) activity due to ALDH1A1 expression, contributes to chemotherapy resistance and tumor relapse. However, clinically applicable inhibitors of ALDH activity have not been reported. There is evidence to suggest that epigenetic regulation of stemrelated genes contributes to chemotherapy efficacy. Here, we show that bromodomain and extraterminal (BET) inhibitors suppress ALDH activity by abrogating BRD4-mediated ALDH1A1 expression through a super-enhancer element and its associated enhancer RNA. The clinically applicable smallmolecule BET inhibitor JQ1 suppressed the outgrowth of cisplatin-treated ovarian cancer cells both in vitro and in vivo. Combination of JQ1 and cisplatin improved the survival of ovarian cancer-bearing mice in an orthotopic model. These phenotypes correlate with inhibition of ALDH1A1 expression through a super-enhancer element and other stem-related genes in promoter regions bound by BRD4. Thus, targeting the BET protein BRD4 using clinically applicable small-molecule inhibitors, such as JQ1, is a promising strategy for targeting ALDH activity in epithelial ovarian cancer.

Original languageEnglish (US)
Pages (from-to)6320-6330
Number of pages11
JournalCancer Research
Volume76
Issue number21
DOIs
StatePublished - Nov 1 2016

Fingerprint

Aldehyde Dehydrogenase
Ovarian Neoplasms
Cisplatin
Drug Therapy
Genetic Promoter Regions
Epigenomics
Genes
Neoplasms
RNA
Phenotype
Recurrence
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yokoyama, Y., Zhu, H., Lee, J. H., Kossenkov, A. V., Wu, S. Y., Wickramasinghe, J. M., ... Zhang, R. (2016). BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. Cancer Research, 76(21), 6320-6330. https://doi.org/10.1158/0008-5472.CAN-16-0854

BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. / Yokoyama, Yuhki; Zhu, Hengrui; Lee, Jeong Heon; Kossenkov, Andrew V.; Wu, Sherry Y.; Wickramasinghe, Jayamanna M.; Yin, Xiangfan; Palozola, Katherine C.; Gardini, Alessandro; Showe, Louise C.; Zaret, Kenneth S.; Liu, Qin; Speicher, David; Conejo-Garcia, Jose R.; Bradner, James E.; Zhang, Zhiguo; Sood, Anil K.; Ordog, Tamas; Bitler, Benjamin G.; Zhang, Rugang.

In: Cancer Research, Vol. 76, No. 21, 01.11.2016, p. 6320-6330.

Research output: Contribution to journalArticle

Yokoyama, Y, Zhu, H, Lee, JH, Kossenkov, AV, Wu, SY, Wickramasinghe, JM, Yin, X, Palozola, KC, Gardini, A, Showe, LC, Zaret, KS, Liu, Q, Speicher, D, Conejo-Garcia, JR, Bradner, JE, Zhang, Z, Sood, AK, Ordog, T, Bitler, BG & Zhang, R 2016, 'BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer', Cancer Research, vol. 76, no. 21, pp. 6320-6330. https://doi.org/10.1158/0008-5472.CAN-16-0854
Yokoyama, Yuhki ; Zhu, Hengrui ; Lee, Jeong Heon ; Kossenkov, Andrew V. ; Wu, Sherry Y. ; Wickramasinghe, Jayamanna M. ; Yin, Xiangfan ; Palozola, Katherine C. ; Gardini, Alessandro ; Showe, Louise C. ; Zaret, Kenneth S. ; Liu, Qin ; Speicher, David ; Conejo-Garcia, Jose R. ; Bradner, James E. ; Zhang, Zhiguo ; Sood, Anil K. ; Ordog, Tamas ; Bitler, Benjamin G. ; Zhang, Rugang. / BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer. In: Cancer Research. 2016 ; Vol. 76, No. 21. pp. 6320-6330.
@article{8d3227d7b8f84d6b9ac2065af2ef0f61,
title = "BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer",
abstract = "The emergence of tumor cells with certain stem-like characteristics, such as high aldehyde dehydrogenase (ALDH) activity due to ALDH1A1 expression, contributes to chemotherapy resistance and tumor relapse. However, clinically applicable inhibitors of ALDH activity have not been reported. There is evidence to suggest that epigenetic regulation of stemrelated genes contributes to chemotherapy efficacy. Here, we show that bromodomain and extraterminal (BET) inhibitors suppress ALDH activity by abrogating BRD4-mediated ALDH1A1 expression through a super-enhancer element and its associated enhancer RNA. The clinically applicable smallmolecule BET inhibitor JQ1 suppressed the outgrowth of cisplatin-treated ovarian cancer cells both in vitro and in vivo. Combination of JQ1 and cisplatin improved the survival of ovarian cancer-bearing mice in an orthotopic model. These phenotypes correlate with inhibition of ALDH1A1 expression through a super-enhancer element and other stem-related genes in promoter regions bound by BRD4. Thus, targeting the BET protein BRD4 using clinically applicable small-molecule inhibitors, such as JQ1, is a promising strategy for targeting ALDH activity in epithelial ovarian cancer.",
author = "Yuhki Yokoyama and Hengrui Zhu and Lee, {Jeong Heon} and Kossenkov, {Andrew V.} and Wu, {Sherry Y.} and Wickramasinghe, {Jayamanna M.} and Xiangfan Yin and Palozola, {Katherine C.} and Alessandro Gardini and Showe, {Louise C.} and Zaret, {Kenneth S.} and Qin Liu and David Speicher and Conejo-Garcia, {Jose R.} and Bradner, {James E.} and Zhiguo Zhang and Sood, {Anil K.} and Tamas Ordog and Bitler, {Benjamin G.} and Rugang Zhang",
year = "2016",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-16-0854",
language = "English (US)",
volume = "76",
pages = "6320--6330",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer

AU - Yokoyama, Yuhki

AU - Zhu, Hengrui

AU - Lee, Jeong Heon

AU - Kossenkov, Andrew V.

AU - Wu, Sherry Y.

AU - Wickramasinghe, Jayamanna M.

AU - Yin, Xiangfan

AU - Palozola, Katherine C.

AU - Gardini, Alessandro

AU - Showe, Louise C.

AU - Zaret, Kenneth S.

AU - Liu, Qin

AU - Speicher, David

AU - Conejo-Garcia, Jose R.

AU - Bradner, James E.

AU - Zhang, Zhiguo

AU - Sood, Anil K.

AU - Ordog, Tamas

AU - Bitler, Benjamin G.

AU - Zhang, Rugang

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The emergence of tumor cells with certain stem-like characteristics, such as high aldehyde dehydrogenase (ALDH) activity due to ALDH1A1 expression, contributes to chemotherapy resistance and tumor relapse. However, clinically applicable inhibitors of ALDH activity have not been reported. There is evidence to suggest that epigenetic regulation of stemrelated genes contributes to chemotherapy efficacy. Here, we show that bromodomain and extraterminal (BET) inhibitors suppress ALDH activity by abrogating BRD4-mediated ALDH1A1 expression through a super-enhancer element and its associated enhancer RNA. The clinically applicable smallmolecule BET inhibitor JQ1 suppressed the outgrowth of cisplatin-treated ovarian cancer cells both in vitro and in vivo. Combination of JQ1 and cisplatin improved the survival of ovarian cancer-bearing mice in an orthotopic model. These phenotypes correlate with inhibition of ALDH1A1 expression through a super-enhancer element and other stem-related genes in promoter regions bound by BRD4. Thus, targeting the BET protein BRD4 using clinically applicable small-molecule inhibitors, such as JQ1, is a promising strategy for targeting ALDH activity in epithelial ovarian cancer.

AB - The emergence of tumor cells with certain stem-like characteristics, such as high aldehyde dehydrogenase (ALDH) activity due to ALDH1A1 expression, contributes to chemotherapy resistance and tumor relapse. However, clinically applicable inhibitors of ALDH activity have not been reported. There is evidence to suggest that epigenetic regulation of stemrelated genes contributes to chemotherapy efficacy. Here, we show that bromodomain and extraterminal (BET) inhibitors suppress ALDH activity by abrogating BRD4-mediated ALDH1A1 expression through a super-enhancer element and its associated enhancer RNA. The clinically applicable smallmolecule BET inhibitor JQ1 suppressed the outgrowth of cisplatin-treated ovarian cancer cells both in vitro and in vivo. Combination of JQ1 and cisplatin improved the survival of ovarian cancer-bearing mice in an orthotopic model. These phenotypes correlate with inhibition of ALDH1A1 expression through a super-enhancer element and other stem-related genes in promoter regions bound by BRD4. Thus, targeting the BET protein BRD4 using clinically applicable small-molecule inhibitors, such as JQ1, is a promising strategy for targeting ALDH activity in epithelial ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=84995694883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995694883&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-0854

DO - 10.1158/0008-5472.CAN-16-0854

M3 - Article

C2 - 27803105

AN - SCOPUS:84995694883

VL - 76

SP - 6320

EP - 6330

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -